SCHEMBL29068639

SCHEMBL29068639

O=C(O)NCc1c(F)cc(F)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
P2RX7 Q99572 3/20 0.40
CNR1 P21554 1/20 0.40
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
MAPK1 P28482 1/20 0.37
RIPK1 Q13546 1/20 0.37
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
THRB P10828 1/20 0.36
MYC P01106 1/20 0.36
WDR5 P61964 1/20 0.36
POU2F2 P09086 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31704838 0.89 ALDH1A1 (0.43) ALDH1A1P2RX7CNR1ROCK2ROCK1
SCHEMBL25840301 0.82 ALDH1A1 (0.50) ALDH1A1P2RX7CNR1ROCK2ROCK1
SCHEMBL25375943 0.81 TACR1 (0.40) ALDH1A1P2RX7CES2EPHX2
SCHEMBL18300420 0.80 GPR35 (0.39) ALDH1A1MYCWDR5EPHX2
SCHEMBL3557822 0.79 CYP1A2 (0.48) ALDH1A1P2RX7ROCK2ROCK1CES2
SCHEMBL29145665 0.79 ALDH1A1 (0.44) ALDH1A1P2RX7CNR1ROCK2ROCK1
SCHEMBL5481957 0.79 CHRM4 (0.45) ALDH1A1P2RX7ROCK2ROCK1CES2
SCHEMBL5644578 0.78 GAA (0.52) ALDH1A1ROCK2ROCK1EPHX2
SCHEMBL18301275 0.78 KLKB1 (0.48) ALDH1A1CYP1A2CYP2D6CYP2C9TSHR
SCHEMBL29999322 0.78 ROCK2 (0.39) ALDH1A1P2RX7ROCK2ROCK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115620-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-10 US disclosed
EP-4438123-A2 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-10-02 EP disclosed
EP-4310087-B1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-07-03 EP disclosed
EP-4310087-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-01-24 EP disclosed
CN-116745292-A Substituted pyridotriazine compounds and uses thereof 吉利德科学公司 2023-09-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115620-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DHFR ALDH1A1 684/4885P2RX7 3917/4885CNR1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.